For the Inventor, By the Inventor

Enter assignee name

Meiji Dairies Corporation

USPTO Granted Patents = 41

% Expired Patents = 48.8

CIPO Patents = 7

EPO Patents = 9

Forward Citations = 132

Loading Chart...

Loading Chart...

103 inventors (with patents filed for the assignee):

Masashi Yamada (13 out of 81 patents)

Hiroto Suzuki (11 out of 14 patents)

Bang Luu (9 out of 11 patents)

4. Yukie Suma (6 out of 7 patents)

5. Masayuki Uchida (4 out of 21 patents)

6. Nobuo Yoda (4 out of 7 patents)

7. Keisuke Furuichi (4 out of 9 patents)

8. Makoto Yamaguchi (3 out of 37 patents)

9. Seiya Makino (3 out of 7 patents)

10. Yoshio Sato (3 out of 18 patents)

11. Shuji Ikegami (3 out of 7 patents)

12. Hisae Kume (3 out of 7 patents)

13. Kenji Mizumoto (3 out of 10 patents)

14. Hajime Sasaki (3 out of 10 patents)

15. Naoki Taketomo (3 out of 6 patents)

Core Competencies:

Peptide Inhibitors

Nutritional Compositions

Dairy Products

Immunostimulation

Inflammatory Bowel Diseases

Amino Acid Composition

Diabetic Complications

Hematopoietic Cell Expansion

Long-Chain Alcohols

Neurodegenerative Diseases

Inflammation Symptoms

Coffee Bean Extract

41 patents: Sort by Forward Citations

1. 8637463 - Peptide inhibiting angiotensin converting enzyme (2014-01-28),

2. 8025911 - Preventive and/or remedy for inflammatory bowel diseases (2011-09-27),

3. 8012926 - Amino acid composition and supplementary liquid containing the same (2011-09-06),

4. 8012924 - Amino acid composition and supplementary liquid containing the same (2011-09-06),

5. 8012524 - Mousse-type spread and mousse-type edible oil (2011-09-06),

6. 7943124 - Composition for immunostimulation (2011-05-17),

7. 7939099 - Sustained improver of muscular fatigue (2011-05-10),

8. 7902249 - Indole derivatives substituted with long-chain alcohols and medicaments containing them (2011-03-08),

9. 7893304 - Hydroquinone long-chain derivatives and/or phenoxy long-chain derivatives, and pharmaceuticals comprising the same (2011-02-22),

10. 7888395 - STAT3 phosphorylation inhibitor and notch1 expression inhibitor (2011-02-15),

11. 7883330 - Powder compression molding machine and apparatus for continuous production of powder compression molded item using the machine (2011-02-08),

12. 7838565 - Use of cyclohexenone derivatives in the manufacture of a medicament for treating diabetic complications (2010-11-23),

13. 7834061 - Process for producing 1,4-dihydroxy-2-naphthoic acid (2010-11-16),

14. 7815947 - Nutritional composition for controlling blood sugar level (2010-10-19),

15. 7771764 - Method for producing an extract of coffee beans (2010-08-10),

Company Overview

Meiji Dairies Corporation, headquartered in Tokyo, Japan, specializes in the development and production of dairy products and nutritional solutions. The company is engaged in advanced research focusing on peptide inhibitors and their applications in inflammatory bowel diseases, as well as the formulation of immunostimulation compositions. Meiji's expertise extends to amino acid composition and adipocyte differentiation inhibitors, contributing to innovative nutritional management strategies and health-oriented products in the food industry.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

41 Patents

#908 in Tokyo

#1,944 in Japan

#16,725 in the World

Meiji Dairies Corporation

Forward Citations = 132

103 inventors:

Masashi Yamada (13 out of 81 patents)

Hiroto Suzuki (11 out of 14 patents)

Bang Luu (9 out of 11 patents)

4. Yukie Suma (6 out of 7 patents)

5. Masayuki Uchida (4 out of 21 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Meiji Dairies Corporation. Retrieved from https://idiyas.com/company/meiji-dairies

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…